Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Langley

Showing results (331-340 of 345) with videos related to

Pageof 35
Sort By:
Infection Control and Hospital Epidemiology|August 18, 2022
Trends in <i>Clostridioides difficile</i> infection rates in Canadian hospitals during the coronavirus disease 2019 (COVID-19) pandemicKelly B Choi, Tim Du, Anada Silva, et al.
Infection Control and Hospital Epidemiology|December 19, 2024
The adoption and compliance to central line-associated bloodstream infection insertion and maintenance bundle programs in intensive care unit settings across CanadaZhi Lin Zhou, Anada Silva, Kristine Cannon, et al.
The Journal of Infectious Diseases|December 9, 2022
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of AgeJavier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, et al.
Open Forum Infectious Diseases|July 13, 2023
Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory IllnessMay ElSherif, Melissa K Andrew, Lingyun Ye, et al.
Emerging Infectious Diseases|April 26, 2022
Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019Tim Du, Kelly B Choi, Anada Silva, et al.
The Pediatric Infectious Disease Journal|July 10, 2024
Population Attributable Risk of Wheeze in 2-<6-Year-old Children, Following a Respiratory Syncytial Virus Lower Respiratory Tract Infection in The First 2 Years of LifeShabir A Madhi, Ana Ceballos, Luis Cousin, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
The Journal of Infectious Diseases|February 1, 2023
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized TrialZourab Bebia, Osvaldo Reyes, Robert Jeanfreau, et al.
Antimicrobial Resistance and Infection Control|April 19, 2023
Antimicrobial use among paediatric inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program, 2017/2018Wallis Rudnick, John Conly, Daniel J G Thirion, et al.
Chest|January 9, 2019
Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPDSunita Mulpuru, Li Li, Lingyun Ye, et al.
Pageof 35

Showing results (331-340 of 345) with videos related to

Sort By:
Pageof 35
Infection Control and Hospital Epidemiology|August 18, 2022
Trends in <i>Clostridioides difficile</i> infection rates in Canadian hospitals during the coronavirus disease 2019 (COVID-19) pandemicKelly B Choi, Tim Du, Anada Silva, et al.
Infection Control and Hospital Epidemiology|December 19, 2024
The adoption and compliance to central line-associated bloodstream infection insertion and maintenance bundle programs in intensive care unit settings across CanadaZhi Lin Zhou, Anada Silva, Kristine Cannon, et al.
The Journal of Infectious Diseases|December 9, 2022
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of AgeJavier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, et al.
Open Forum Infectious Diseases|July 13, 2023
Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory IllnessMay ElSherif, Melissa K Andrew, Lingyun Ye, et al.
Emerging Infectious Diseases|April 26, 2022
Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019Tim Du, Kelly B Choi, Anada Silva, et al.
The Pediatric Infectious Disease Journal|July 10, 2024
Population Attributable Risk of Wheeze in 2-<6-Year-old Children, Following a Respiratory Syncytial Virus Lower Respiratory Tract Infection in The First 2 Years of LifeShabir A Madhi, Ana Ceballos, Luis Cousin, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
The Journal of Infectious Diseases|February 1, 2023
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized TrialZourab Bebia, Osvaldo Reyes, Robert Jeanfreau, et al.
Antimicrobial Resistance and Infection Control|April 19, 2023
Antimicrobial use among paediatric inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program, 2017/2018Wallis Rudnick, John Conly, Daniel J G Thirion, et al.
Chest|January 9, 2019
Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPDSunita Mulpuru, Li Li, Lingyun Ye, et al.
Pageof 35